Hjem › Akut bifænotypisk leukæmi › Georgia
Akut bifænotypisk leukæmi kliniske forsøg i Georgia
9 studier for Akut bifænotypisk leukæmi søger deltagere på steder i Georgia.
Byer i Georgia
Officiel studietekst (engelsk)
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- Emory University, Atlanta
RekruttererFase 1
Alder 12 til 78 · Alle køn · Opdateret 29. sep. 2026 · NCT03802695Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
RekruttererFase 2
365 Days · Alle køn · Opdateret 25. sep. 2026 · NCT06317662A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- Emory Winship Cancer Institute, Atlanta
RekruttererFase 1/2
30 Days · Alle køn · Opdateret 16. sep. 2026 · NCT04065399Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Augusta University Medical Center, Augusta
- Atrium Health Navicent, Macon
- og 1 flere
RekruttererFase 3
365 Days – 25 Years · Alle køn · Opdateret 25. aug. 2026 · NCT03959085The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta
- Memorial Health University Medical Center, Savannah
RekruttererFase 1/2
Op til 22 år · Alle køn · Opdateret 25. aug. 2026 · NCT04726241Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Healthcare of Atlanta, Atlanta
RekruttererFase 1
Alder 1 til 30 · Alle køn · Opdateret 3. aug. 2026 · NCT06177067Venetoclax Basket Trial for High Risk Hematologic Malignancies
- Children's Healthcare of Atlanta at Arthur M. Blank Hospital, Atlanta
RekruttererFase 1
Alder 1 til 40 · Alle køn · Opdateret 12. mar. 2026 · NCT05292664Pharmacokinetic and Safety Study of MRX-2843 in Adolescents and Adults With Relapsed/Refractory AML, ALL, or MPAL
- Emory University - WINSHIP Cancer Center, Atlanta
- Emory University, Children's Healthcare of Atlanta, Atlanta
RekruttererFase 1
Alder 12 og opefter · Alle køn · Opdateret 8. jan. 2026 · NCT04872478Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- Children's Healthcare of Atlanta, Emory University, Atlanta
RekruttererFase 1
Alder 1 til 21 · Alle køn · Opdateret 6. dec. 2024 · NCT05476770Fra ClinicalTrials.gov, data hentet 5. okt. 2026. Hver studie har sine egne kvalifikationskrav; studieteamet afgør, hvem der kan deltage.